The Alliance Boots LBO: How KKR and Stefano Pessina Took the First FTSE 100 Company Private — and Exited Through a Two-Step Merger With Walgreens

The mega-LBO exit playbook of the mid-2010s was a template you could recite from memory. Hold the asset for five to seven years. Grow the earnings, pay down some debt, refinance the rest. File the S-1. Price the IPO at a premium to the last private mark. Sell down the residual stake through secondary offerings over two or three years. Book the MOIC when the last block clears. Hilton exited that way. HCA exited that way. Dollar General exited that way.

Alliance Boots did not. KKR and Stefano Pessina spent £11.1 billion in 2007 to take Alliance Boots private — the largest European LBO in history and the first FTSE 100 constituent ever bought out by private equity — and then exited seven and a half years later through a two-step strategic merger with Walgreens that ended with roughly $9.3 billion of cash and 227.7 million Walgreens Boots Alliance shares in the sponsors' hands. No IPO, no S-1, no roadshow. The whole exit ran through a Delaware holding-company reorganization on New Year's Eve 2014.

This post walks through why that structure was the right answer for this specific asset, what it tells you about mega-LBO exits when the IPO window is not the obvious lane, and how a large operator-co-investor changes the exit calculus for a sponsor.

The 2007 entry — a peak-cycle bidding war, a first-of-its-kind take-private

The bidding started on March 9, 2007, when KKR and Stefano Pessina — the Italian-born Executive Deputy Chairman of Alliance Boots and the largest individual shareholder in the merged Boots Group + Alliance UniChem — announced an approach at £10.90 per share, a 15.9% premium to the March 8 close. Terra Firma Capital Partners (Guy Hands), backed by a consortium including the Wellcome Trust and HBOS, entered a competing bid within weeks. The two consortia traded offers into June, and on June 20 the KKR + Pessina consortium's final bid of £11.15 per share was recommended by the Alliance Boots board. That price was 36.8% above the undisturbed February 8, 2007 price and valued the equity at approximately £11.1 billion — roughly $22 billion at then-prevailing exchange rates.

The deal cleared the European Commission on June 15, 2007, was sanctioned by the UK courts under the scheme of arrangement on June 20, and Alliance Boots delisted from the London Stock Exchange on July 26, 2007. The transaction became the first take-private of a FTSE 100 constituent in the index's history, and it remains the largest European LBO ever.

Here is what the transaction looked like at close:

Two things about the sources & uses are worth flagging. First, the equity ownership was structured across three layers — KKR's fund equity, Pessina's personal + Alliance Santé rollover, and the eight-bank equity underwriting piece — with the debt syndicate itself taking a material equity strip. That is a hangover from a specific 2006-2007 practice where debt underwriters were compensated in part with equity kickers on the largest deals. Second, KKR's £1.22 billion equity check was roughly 31% of the new equity in the deal. That percentage matters at exit, because Step 1 and Step 2 proceeds ultimately flowed to holders in proportion to those ownership stakes.

The credit crisis lands, and the debt does not clear

The Alliance Boots syndication was one of the last mega-LBO debt raises to price at pre-crisis terms. It was underwritten in Q2 2007 and was still being placed with institutional loan investors in August when the credit market seized. Contemporaneous market reporting indicated that approximately £5 billion of the £9 billion of new Alliance Boots debt did not clear primary syndication and sat on the eight underwriting banks' balance sheets into 2008 before being sold in the secondary loan market at material discounts to par. That warehouse loss became one of the industry's early canonical examples of "hung deal" underwriter risk on the last-of-the-boom mega-LBOs — the same pattern that would repeat a few months later on the TXU and Harrah's syndications (see Harrah's / Caesars and TXU / Energy Future Holdings for cousin cases).

For KKR and Pessina, though, the debt was already down at the operating company. The paper trading at a discount in the secondary market was a problem for Deutsche Bank and Citi, not for Alliance Boots' capital structure. The company's leverage at close ran high but sustainable against a resilient specialty-pharmacy earnings stream — wholesale drug distribution across Europe, retail pharmacy through the Boots UK chain, and a beauty-and-personal-care contribution manager, all of which generated cash through the 2008-2009 downturn.

The next five years were quieter than any of the mid-decade US mega-LBOs. There was no dividend recap of note, no restructuring, no covenant amendment cycle of the sort that hit Hilton in 2010 (see Blackstone's 2010 Hilton restructuring). The debt got paid down through operating cash flow. Pessina, who by 2010 was Alliance Boots' CEO, ran the operating playbook he had been executing for two decades on the Alliance UniChem side of the merged business — European wholesale expansion, Boots UK format optimization, gross-margin discipline on the beauty categories. By 2012 the earnings were meaningfully above the 2007 diligence base.

Which brings us to Walgreens.

The Step 1 deal — a 45% strategic sale with an embedded option

On June 19, 2012 Walgreens announced a two-step strategic transaction to acquire 100% of Alliance Boots. The structure was novel enough that a good portion of the sell-side research on the announcement day read as an attempt to reverse-engineer what the parties were actually trying to accomplish.

The mechanics of Step 1 were simple. Walgreens paid $4.0 billion in cash plus 83.4 million newly-issued Walgreens common shares to the Alliance Boots shareholder group in exchange for a 45% equity interest in Alliance Boots plus three of nine board seats. Walgreens' closing share price on the day before announcement (June 18, 2012) was $31.96, valuing the stock consideration at approximately $2.7 billion. Total Step 1 transaction value was therefore approximately $6.7 billion, implying an enterprise valuation for 100% of Alliance Boots of approximately $14.8 billion at the transaction reference.

Step 1 also created the option that made Step 2 mechanical rather than negotiated. Under the transaction agreements:

• Walgreens received a call option to acquire the remaining 55% of Alliance Boots.
• The Alliance Boots shareholder group received a put option requiring Walgreens to acquire the remaining 55%.
• The consideration under either option was formula-based: $9.5 billion in cash plus 144.3 million Walgreens shares.
• The exercise window opened on the 30-month anniversary of Step 1 close and remained open for 18 months thereafter.

For KKR, the Step 1 mechanics meant an immediate partial monetization: KKR's proportional share of the Step 1 proceeds was approximately $1.8 billion in cash plus 7 million Walgreens shares (~$0.2 billion at the reference price). That partial exit at year 5 of the hold put nearly all of KKR's original $2.45 billion equity check back in the fund, in cash, while leaving KKR holding roughly 31% of a business that had a formula-priced call sitting on top of it for the rest.

Structurally, Step 1 achieved three things at once. It let KKR de-risk the timing question that dominates every mega-LBO's back half — is the IPO window open, is the strategic bid environment favorable, are the LP quarterly marks holding up? — by crystallizing cash from a partial exit right away. It let Walgreens preview the asset in real time, with board seats and consolidated financial reporting, before committing to Step 2. And it let Pessina keep operating the business as CEO of the still-independent Alliance Boots, without the disruption of a full merger and post-close integration mid-hold.

The Step 2 deal — a New Year's Eve merger and a new NASDAQ listing

On August 6, 2014 — a few months before the earliest exercisable date under the Step 1 option window — Walgreens announced that it was accelerating Step 2 to close on December 31, 2014. Walgreens' board and management had decided they had seen enough of Alliance Boots' post-Step-1 performance to commit early.

Step 2 was structured as a full holding-company reorganization. On December 31, 2014, Walgreen Co. and Alliance Boots each became wholly-owned subsidiaries of a newly-formed Delaware holding company, Walgreens Boots Alliance, Inc. Walgreens' NYSE listing (ticker WAG) was replaced by WBA on NASDAQ effective the same day. WAG shareholders received one share of WBA for each share of WAG.

The consideration paid to the Alliance Boots shareholder group at Step 2 was $5.3 billion in cash plus 144.3 million shares of new WBA common stock. That was $4.2 billion of cash less than the original Step 1 formula (roughly reflecting revisions negotiated between the parties in the August 6, 2014 acceleration agreement) but the same share count.

Aggregating the two steps, Walgreens paid the Alliance Boots shareholder group approximately:

At WBA's December 31, 2014 opening price (around the mid-$70s), the 227.7 million WBA shares had a market value of roughly $17-18 billion, giving Walgreens' aggregate total consideration to the Alliance Boots shareholder group of approximately $27-28 billion in cash-plus-stock — comfortably above the £11.1 billion / $22 billion 2007 purchase price. The KKR + Pessina consortium had roughly doubled the enterprise value of Alliance Boots, in dollar terms, over the 7.5-year hold.

The returns — what KKR itself made, and why the IRR question is hard

KKR has not publicly disclosed a definitive MOIC or IRR for the Alliance Boots investment. But the arithmetic of KKR's disclosed proceeds against its £1.22 billion / $2.45 billion equity check produces an estimated aggregate return of roughly 2.5x-2.9x in cash-plus-stock value at the December 31, 2014 close, over 7.5 years. In November 2014 KKR co-founder Henry Kravis publicly described Alliance Boots as "one of our best-ever investments" at a Goldman Sachs conference — which, coming from the founder of the firm that also did HCA (see The HCA LBO) and Dollar General (see The Dollar General LBO), sets a fairly clear ceiling on how much bigger the number could reasonably have been.

The IRR is genuinely hard to pin down without KKR's cash-flow schedule, because it depends heavily on the timing split between Step 1 (2012) and Step 2 (2014) proceeds. Consider the sensitivity:

Even under the most sponsor-favorable assumption, the IRR sits in the mid-teens — solid, not heroic, and consistent with what a well-executed long-hold mega-LBO with meaningful multiple expansion typically produces. See MOIC vs IRR for why the answer to "which of those two numbers is the right one to focus on" depends entirely on what a fund's LPs need from the investment.

The KKR-specific answer here is that the fund's LPs valued the certainty of the strategic-merger exit and the partial monetization at year 5 more than they would have valued a marginally higher IRR at a marginally later single-event exit. When you can lock in a 2.7x on a $2.45 billion equity check across a two-step process with an option-embedded second leg, you take it.

Why the strategic-merger exit was the right structure for this asset

Look at the alternatives KKR realistically had at Step 1. Option A was a UK IPO of Alliance Boots. That would have required underwriting London-market demand for a levered UK/European specialty-pharmacy platform at a moment when the UK IPO market was recovering unevenly from the crisis. Option B was a US IPO. That would have required either restructuring the domicile or dual-listing, both expensive and slow. Option C was a secondary sale to another sponsor — a levered buyer paying a levered price on top of existing leverage, at a moment when secondary LBO activity was still muted. Option D was continued private ownership indefinitely, with a formal exit deferred to some later window.

Option E — the two-step strategic merger — solved the underlying constraint that made A, B, and C awkward. The natural strategic acquirer for Alliance Boots was Walgreens: same category, adjacent geography, publicly-listed equity currency, a balance sheet that could underwrite the cash portion of the consideration. And the two-step structure specifically converted a full-takeout negotiation into a partial-sale-plus-option, which is a much easier thing to price when neither party wants to commit to a full 100% transaction on day one.

Which surfaces the more general point. The mega-LBO exit set is not IPO-or-secondary-sale. It is IPO, secondary sale to another sponsor, secondary sale to a strategic, or a structured combination like Alliance Boots. Which one dominates depends on the specific asset, the specific window, and the specific mix of natural acquirers. For a UK/European specialty pharmacy platform in 2012-2014, the structured strategic merger with Walgreens dominated the alternatives. For a US hotel platform in 2013 (see Hilton IPO), the multi-year IPO sell-down dominated. Do not assume the template that worked for the last comparable deal is the right one for yours.

The operator co-investor as a structural feature

One more feature of the Alliance Boots deal worth calling out. Pessina was not a management-team rollover minority holder in the customary "0.5% of the equity in the LTIP" sense. He was the largest individual pre-deal shareholder in Alliance Boots and one of the two named principals on the buyout bid. His equity contribution was on the same order of magnitude as some of the bank-syndicate co-invests. And he ran the company as CEO through the second half of the hold.

That kind of operator co-investment changes the exit incentive structure in a specific and important way. KKR, as a fund sponsor, operates on a defined LP-driven hold constraint: five to seven years is the standard sweet spot for a fund vintage, and pushing beyond that becomes a conversation with LPs about extension fees and continuation vehicles. Pessina, as an operator with a personal equity stake, had no such constraint. He could credibly want to run Alliance Boots for another decade if the structure was wrong, and he had the practical ability to block any exit path he did not like.

That dynamic pushed the exit toward the option-embedded, two-step structure that Alliance Boots actually got. A pure fund-sponsor exit — one where the sponsor is the only holder with a strong view on timing — would probably have accepted an IPO in 2013 at whatever price cleared the book. A pure-operator exit — one where the operator dominates the timing decision — would probably have deferred the exit indefinitely. The 2012-2014 Walgreens structure is what a middle path between those two positions looks like.

What the deal did not do — the 2019 re-LBO attempt that did not close

Postscript worth noting. In November 2019, roughly five years after the Alliance Boots exit closed, KKR made an unsolicited approach to take Walgreens Boots Alliance private in what would have been the largest LBO in history at approximately $70 billion. The approach did not proceed to a definitive agreement. But it underscores a specific pattern in mega-cap consumer PE: the same asset can move in and out of PE ownership multiple times over a decade. If public equity investors are unwilling to hold a levered mature consumer platform at a favorable multiple, PE sponsors will assess whether the asset is worth taking private again — even one they exited five years earlier.

What to take from this

Three practical lessons for anyone underwriting or exiting a mega-LBO of a mature consumer platform:

1. Do not assume IPO is the exit. The mega-LBO exit set includes structured strategic mergers, and for the right asset a two-step transaction with an option-embedded second leg dominates a single-event public listing. Under a sponsor-modeling framework you might want to build the WACC / cost-of-capital comparison between a strategic buyer and a public-market equity holder for your specific asset before defaulting to the IPO lane.

2. Front-load the partial exit if the option is available. KKR's Step 1 partial monetization at year 5 put roughly $2 billion back in the fund while leaving upside on the remaining 55%. That structure meaningfully improves interim IRR marks and DPI even if it does not maximize headline aggregate MOIC. See MOIC vs IRR for how these two numbers move differently when proceeds are unevenly timed.

3. Model the operator co-investor's incentives separately from the fund's. A large operator co-investor with a decades-long stake in the platform has a different indifference curve on exit timing than a fund sponsor with a defined LP-driven hold. Structuring the exit to satisfy both requires option-embedded, partial-exit designs of the sort Alliance Boots used. If you're stress-testing the returns waterfall for a deal with a heavy operator co-invest, run at least one scenario where the operator vetoes the fund's preferred exit window.

---

If you're building or reviewing an LBO model — one where the exit path is not obviously "IPO in year 5" — the All-in-One PE Model contains an integrated capital-structure module that lets you model multi-step exit sequences with cash-plus-stock consideration and separately-timed sponsor distributions. The returns and MOIC waterfall will give you the sensitivity table for how much the exit-timing profile changes the sponsor IRR at a constant aggregate MOIC. See the sheet preview for how the model handles two-step exits with formula-priced call/put options.

---

Sources:

• Walgreens Boots Alliance, Inc. Form 8-K12B (Dec 31, 2014) — Step 2 acquisition closing, holding company reorganization, and WBA listing effective date
• Walgreens Boots Alliance, Inc. Form 8-K Exhibit 99.1 (Dec 31, 2014) — press release announcing completion of the Alliance Boots Step 2 acquisition
• Walgreens Boots Alliance, Inc. Form S-4 (Aug 2014) — Step 2 merger registration statement
• Walgreens Boots Alliance, Inc. Form 424B3 (Oct 2014) — Step 2 merger prospectus
• Walgreens Boots Alliance, Inc. Form SC 13D (Dec 2014) — beneficial ownership disclosures for KKR and Stefano Pessina following Step 2
• Alliance Boots GmbH Audited Consolidated Financial Statements (SEC exhibit, Aug 2012)
• KKR & Co. L.P. Form 8-K Exhibit 99.1 (June 19, 2012) — press release announcing the Walgreens / Alliance Boots Step 1 strategic transaction
• European Commission decision (June 15, 2007) — clearance of the acquisition of Alliance Boots plc by KKR and Stefano Pessina (Practical Law summary)
• BusinessWire: "KKR sells remaining stake in Alliance Boots" (Dec 31, 2014)
• Euromoney: "Private equity: KKR strategy pays off with Alliance Boots sale"
• City A.M.: "KKR cashes in as Boots sold in $16bn plan"
• Bloomberg: "Taking Walgreens Private for $70 Billion Is Pricey Even for KKR" (Nov 21, 2019)
• Gulf News (Reuters wire): "Walgreen to buy 45% stake in Alliance Boots for $6.7b"
• NBC News (AP wire): "Walgreen pays $6.7B for stake in Alliance Boots"